TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05030506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: 40 mg tablet administered orally at a dose of 120 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: 40 mg tablet administered orally at a dose of 120 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 10 mg capsule administered orally at a dose of 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 10 mg capsule administered orally at a dose of 20 mg
Study: NCT06451042

Intervention type: DIAGNOSTIC_TEST
Intervention: FET-PET/MRI
Description: Radiation planning target volume (PTV) when planned with FET-PET/MRI to PTV when planned with conventional (Standard of Care) MRI only. 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) 180-200 megabecquerel (MBq) administered intravenously prior to PET/MRI imaging.
Study: NCT06323460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05988398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READY To Stand Curriculum
Description: Students will receive the RTS programming over six consecutive school days, spread over two weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
Study: NCT05420207

Intervention type: OTHER
Intervention: No intervention
Description: No intervention included

Intervention type: OTHER
Intervention: No intervention
Description: No intervention included
Study: NCT06496009

Intervention type: DRUG
Intervention: PD-1 Inhibitors
Description: advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice
Study: NCT05854524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: The intervention is exercise and there are no drugs or devices used in this trial. The exercise consists of two intensity levels of a 30-minute aerobic exercise intervention with both arms crossing over to both conditions: low intensity exercise (60-70% of estimated maximum heart rate (EMRH)) and moderate-vigorous intensity exercise (75-85% of EMHR).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: The intervention is exercise and there are no drugs or devices used in this trial. The exercise consists of two intensity levels of a 30-minute aerobic exercise intervention with both arms crossing over to both conditions: low intensity exercise (60-70% of estimated maximum heart rate (EMRH)) and moderate-vigorous intensity exercise (75-85% of EMHR).
Study: NCT04812522

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clean Cut program
Description: Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clean Cut program
Description: Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clean Cut program
Description: Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clean Cut program
Description: Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clean Cut program
Description: Clean Cut, is an adaptive, multimodal surgical infection prevention program that integrates perioperative process improvement and patient outcomes measurement using process mapping, training and improved management practices, and compliance with critical standards of surgical antisepsis
Study: NCT05383755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention for pregnant adolescents living with HIV
Description: The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will be use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.
Study: NCT06358092

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic venous pressure gradient
Description: HVPG is a measurement used to assess portal hypertension, a condition characterized by increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. HVPG measurement involves inserting a catheter into the hepatic vein via jugular vein puncture to directly measure the pressure within the liver. By comparing the pressure in the hepatic vein with that in the portal vein, HVPG provides valuable information about the severity of portal hypertension and helps in predicting clinical outcomes in patients with liver cirrhosis and related conditions. HVPG measurements are crucial in guiding treatment decisions, assessing treatment response, and predicting the risk of complications such as variceal bleeding and liver failure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic venous pressure gradient
Description: HVPG is a measurement used to assess portal hypertension, a condition characterized by increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. HVPG measurement involves inserting a catheter into the hepatic vein via jugular vein puncture to directly measure the pressure within the liver. By comparing the pressure in the hepatic vein with that in the portal vein, HVPG provides valuable information about the severity of portal hypertension and helps in predicting clinical outcomes in patients with liver cirrhosis and related conditions. HVPG measurements are crucial in guiding treatment decisions, assessing treatment response, and predicting the risk of complications such as variceal bleeding and liver failure.
Study: NCT06078033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Sustained neutral apophyseal glide (SNAG) mobilization with movement applied to targeted vertebra while patients performed their painful movement.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham mobilization with movement
Description: Manual contact (without any pressure) applied to targeted vertebra while patients performed their painful movement.
Study: NCT04891900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
Description: Initial treatment (6 cycles)：~1. TQB2450：1200 mg , Day 1 ivgtt ,once every 3 weeks~2. Anlotinib: 10 mg/day orally ，from days 1 to 14 in a 21-day cycle~3. Oxaliplatin: 130 mg / m2, Day 1 ivgtt ,once every 3 weeks~4. Capecitabine: 1000 mg / m2, orally, twice a day (once in the morning and once in the evening), from days 1 to 14 in a 21-day cycle Maintenance treatment：~1）TQB2450: 1200 mg , Day 1 ivgtt , once every 3 weeks 2）Anlotinib: 10 mg/day orally , from days 1 to 14 in a 21-day cycle
Study: NCT06358092

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-Dimensional Shear Wave Elastography
Description: 2D-SWE is a non-invasive imaging technique used to assess tissue stiffness, particularly in the liver. This technology utilizes ultrasound to generate shear waves within the tissue being examined. By measuring the speed of these shear waves as they propagate through the tissue, 2D-SWE can provide quantitative information about tissue elasticity or stiffness. In the context of liver disease, including cirrhosis and fibrosis, 2D-SWE is valuable for evaluating the degree of liver stiffness, which correlates with the severity of liver fibrosis. This information aids in diagnosis, staging, and monitoring of liver diseases, allowing for early detection of complications and assessment of treatment response. Compared to traditional biopsy-based methods, 2D-SWE offers the advantage of being non-invasive, rapid, and repeatable, making it a preferred modality for assessing liver stiffness in clinical practice.

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-Dimensional Shear Wave Elastography
Description: 2D-SWE is a non-invasive imaging technique used to assess tissue stiffness, particularly in the liver. This technology utilizes ultrasound to generate shear waves within the tissue being examined. By measuring the speed of these shear waves as they propagate through the tissue, 2D-SWE can provide quantitative information about tissue elasticity or stiffness. In the context of liver disease, including cirrhosis and fibrosis, 2D-SWE is valuable for evaluating the degree of liver stiffness, which correlates with the severity of liver fibrosis. This information aids in diagnosis, staging, and monitoring of liver diseases, allowing for early detection of complications and assessment of treatment response. Compared to traditional biopsy-based methods, 2D-SWE offers the advantage of being non-invasive, rapid, and repeatable, making it a preferred modality for assessing liver stiffness in clinical practice.
Study: NCT05870033

Intervention type: DEVICE
Intervention: Electromyography (EMG) measurement
Description: Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks

Intervention type: DEVICE
Intervention: Electromyography (EMG) measurement
Description: Electromyography (EMG) measurement of m. quadriceps femoris and semitendinosus muscle during static functional tasks
Study: NCT04754776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 RVF
Description: Single dose of ChAdOx1 RVF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 RVF
Description: Single dose of ChAdOx1 RVF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 RVF
Description: Single dose of ChAdOx1 RVF
Study: NCT04956458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar motion style acupuncture treatment
Description: Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study: NCT06376240

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxamine 300mg per day
Description: oral supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxamine 300mg per day
Description: oral supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 300mg placebo per day
Description: oral supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo 300mg placebo per day
Description: oral supplement
Study: NCT04706143

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccines
Description: different available vaccines: live inactivated, mRNA and viral vector vaccines
Study: NCT05417308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: Applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04436965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
Study: NCT05170178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inclusion and familiarization
Description: * presentation of the study purpose and the protocol to the volunteer~* clinical examination to check inclusion and exclusion criteria~* Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inclusion and familiarization
Description: * presentation of the study purpose and the protocol to the volunteer~* clinical examination to check inclusion and exclusion criteria~* Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inclusion and familiarization
Description: * presentation of the study purpose and the protocol to the volunteer~* clinical examination to check inclusion and exclusion criteria~* Familiarization with the crying of one assigned baby, by listening to several bath cries from this baby

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI acquisition and closure
Description: * Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~* MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~* debriefing~* Protocol ending
Study: NCT04436965

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
Study: NCT05705245

Intervention type: OTHER
Intervention: recruitment
Description: Automated alveolar recruitment menouever applied during mechanical ventilation in the intraoperative period
Study: NCT05170178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI acquisition and closure
Description: * Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~* MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~* debriefing~* Protocol ending

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI acquisition and closure
Description: * Second phase of familiarization, listening again to bath cries of their assigned baby. These cries will be different from those listened during the first familiarization phase.~* MRI acquisition: after acquisition of the anatomical images (5 min), the subjects will listen to 64 cries divided into 4 functional MRI sessions of 10 minutes each. The cries will be those of their baby or of unknown babies, evoked in a painful (vaccination) or a non-painful (bath) situation, presented in a pseudo-random order. Participants will be asked to assess whether they recognize their baby (yes/no) and whether they recognize a pain cry (yes/no).~* debriefing~* Protocol ending
Study: NCT05213923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ED Sepsis Tracking Sheet
Description: Implementation of an ED Sepsis Tracking Sheet. This sheet will track time of patient presentation, time of High-Acuity Medical Response (HAMR) page, time of bilateral 18g or larger IV access, time of initial lactate, time two sets of blood cultures were sent, time antibiotics were administered as well as which antibiotics and what dose, time initial IV fluid bolus was completed, time repeat lactate was sent, timing of post-IV-fluid bolus vital signs, as well as the presence of persistent hypotension following this IV fluid bolus and whether or not vasopressors were applied.
Study: NCT05107232

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI
Study: NCT05931328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa combined with pomalidomide
Description: thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
Study: NCT06115265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Fat diet
Description: KDDP and NDPP will deliver identical comprehensive lifestyle counseling and follow up to participants, but dietary interventions in each group will differ, with KDDP participants receiving a ketogenic diet and NDPP participants receiving a low fat diet.